GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Epb41l5 | affects expression | ISO | EPB41L5 (Homo sapiens) | 6480464 | CTD | Valproic Acid affects the expression of EPB41L5 mRNA | PMID:25979313 PMID:26272509 | Epb41l5 | decreases expression | ISO | EPB41L5 (Homo sapiens) | 6480464 | CTD | Valproic Acid results in decreased expression of EPB41L5 mRNA | PMID:23179753 PMID:24935251 | Epb41l5 | decreases methylation | ISO | EPB41L5 (Homo sapiens) | 6480464 | CTD | Valproic Acid results in decreased methylation of EPB41L5 gene | PMID:29154799 | Epb41l5 | increases expression | ISO | EPB41L5 (Homo sapiens) | 6480464 | CTD | Valproic Acid results in increased expression of EPB41L5 mRNA | PMID:24383497 PMID:24935251 PMID:28001369 | Epb41l5 | multiple interactions | ISO | EPB41L5 (Homo sapiens) | 6480464 | CTD | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPB41L5 mRNA; [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L5 mRNA | PMID:27188386 | |
Go Back to source page | Continue to Ontology report |